S&P 500 Futures
(0.12%) 5 333.50 points

Dow Jones Futures
(0.06%) 40 162 points

Nasdaq Futures
(0.17%) 18 667 points

Oil
(0.29%) $80.29

Gas
(1.94%) $2.68

Gold
(1.43%) $2 452.00

Silver
(3.41%) $32.33

Platinum
(0.47%) $1 095.10

USD/EUR
(-0.09%) $0.919

USD/NOK
(-0.08%) $10.67

USD/GBP
(0.03%) $0.787

USD/RUB
(0.11%) $91.07

Realtime updates for Abionyx Pharma SA [ABNX.PA]

Exchange: EURONEXT Industry: Biotechnology

Last Updated17 May 2024 @ 11:37

25% discount on Stockinvest.us - Use code: Podcast

-6.68% € 1.090

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 11:37):

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis...

Stats
Today's Volume	98 329.00
Average Volume	49 655.00
Market Cap	35.07M
EPS	€0 ( 2024-04-24 )
Next earnings date	( €0 ) 2024-06-26
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-9.08
ATR14	€0.0150 (1.38%)

Volume Correlation

Long: -0.03 (neutral)

Short: -0.46 (neutral)

Signal:(47.981) Neutral

Abionyx Pharma SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Abionyx Pharma SA Correlation - Currency/Commodity

0.71
( moderate )

0.75
( moderate )

0.00
( neutral )

0.77
( moderate )

0.00
( neutral )

-0.70
( moderate negative )

Abionyx Pharma SA Financials

Annual	2023
Revenue:	€4.64M
Gross Profit:	€1.14M (24.59 %)
EPS:	€-0.120

FY	2023
Revenue:	€4.64M
Gross Profit:	€1.14M (24.59 %)
EPS:	€-0.120

FY	2022
Revenue:	€5.25M
Gross Profit:	€636 000 (12.11 %)
EPS:	€-0.150

FY	2021
Revenue:	€675 000
Gross Profit:	€259 000 (38.37 %)
EPS:	€-0.283

Financial Reports:

No articles found.

Abionyx Pharma SA Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Abionyx Pharma SA

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.